{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:35:58Z","timestamp":1793277358492,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007605","name":"Aarhus Universitet","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007605","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Oxaliplatin-induced peripheral neuropathy (OIPN) is a chronic, debilitating late effect following oxaliplatin treatment. Neurofilament light chain (NfL) is a structural protein found in nerve axons that was investigated upon oxaliplatin exposure in vitro and in vivo correlated to symptoms of OIPN in colorectal cancer patients receiving oxaliplatin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Human sensory neurons, derived from induced pluripotent stem cells, were exposed to clinically relevant concentrations of oxaliplatin in vitro, with NfL concentrations measured in the cell medium. The prospective clinical study included patients with colorectal cancer undergoing chemotherapy therapy with or without oxaliplatin. Possible OIPN was defined as bilateral presence of numbness and\/or presence of pricking sensations in the feet documented in an interview at the time of blood sampling prior to, 3, and 6 months after initiating treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Oxaliplatin exposure led to a dose-dependent NfL increase\n                      <jats:italic>in vitro.<\/jats:italic>\n                      In the clinical cohort of 30 patients (18 in the oxaliplatin group), NfL levels rose at 3 and 6 months compared to controls. NfL level changes correlated to OIPN symptoms at the 6-month timepoint (rho 0.81,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). However, the interindividual variation was substantial, and most patients showed only a minor increase in NfL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both in vitro and clinical data indicate that oxaliplatin exposure results in elevated NfL levels. Further prospective studies are needed to evaluate NfL as an early biomarker for OIPN, specifically focusing on the timing of blood sampling during chemotherapy treatment to enable the timely reduction of oxaliplatin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00280-025-04773-w","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T23:34:37Z","timestamp":1744241677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Neurofilament light chain as a marker for neuronal damage: integrating in vitro studies and clinical findings in patients with oxaliplatin-induced neuropathy"],"prefix":"10.1007","volume":"95","author":[{"given":"Nina Lykkegaard","family":"Gehr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore B.","family":"Stage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malene Roland Vils","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Rafael","family":"Rafaelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonna Skov","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte Aalund","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"Timm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Henrik","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben Fr\u00f8strup","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna Brix","family":"Finnerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Ventzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"4773_CR1","doi-asserted-by":"publisher","unstructured":"Bennedsgaard K, Ventzel L, Themistocleous AC, Bennett DL, Jensen AB, Jensen AR et al (2020) Long-term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy. April 5114\u20135123. https:\/\/doi.org\/10.1002\/cam4.3129","DOI":"10.1002\/cam4.3129"},{"issue":"Suppl 1","key":"4773_CR2","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.3816\/ccc.2005.s.006","volume":"5","author":"A Grothey","year":"2005","unstructured":"Grothey A (2005) Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 5(Suppl 1):S38\u201346. https:\/\/doi.org\/10.3816\/ccc.2005.s.006","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"4773_CR3","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/j.pain.0000000000000404","volume":"157","author":"L Ventzel","year":"2016","unstructured":"Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB (2016) Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain 157(3):560\u2013568. https:\/\/doi.org\/10.1097\/j.pain.0000000000000404","journal-title":"Pain"},{"key":"4773_CR4","doi-asserted-by":"publisher","unstructured":"Mols F, Beijers T, Vreugdenhil G (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. 2261\u20132269. https:\/\/doi.org\/10.1007\/s00520-014-2255-7","DOI":"10.1007\/s00520-014-2255-7"},{"key":"4773_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fphar.2017.00086","volume":"8","author":"N Kerckhove","year":"2017","unstructured":"Kerckhove N, Collin A, Conde S, Chaleteix C, Pezet D, Balayssac D (2017) Long-Term effects, pathophysiological mechanisms, and risk factors of Chemotherapy-Induced peripheral neuropathies: A comprehensive literature review. Front Pharmacol 8:86. https:\/\/doi.org\/10.3389\/fphar.2017.00086","journal-title":"Front Pharmacol"},{"key":"4773_CR6","doi-asserted-by":"publisher","unstructured":"Cavaletti G, D\u2019Acunti A, Porcu A, Masiello G, Del Campo L, Tracl\u00f2 G et al (2023) Self-Reported assessment of the Socio-Economic impact of anticancer Chemotherapy-Related neurotoxicity. Toxics 11(2). https:\/\/doi.org\/10.3390\/toxics11020104","DOI":"10.3390\/toxics11020104"},{"issue":"6","key":"4773_CR7","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/jnnp-2017-317215","volume":"89","author":"A Shah","year":"2018","unstructured":"Shah A, Hoffman EM, Mauermann ML, Loprinzi CL, Windebank AJ, Klein CJ et al (2018) Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry 89(6):636\u2013641. https:\/\/doi.org\/10.1136\/jnnp-2017-317215","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4773_CR8","doi-asserted-by":"publisher","first-page":"913848","DOI":"10.1155\/2012\/913848","volume":"2012","author":"CT Pike","year":"2012","unstructured":"Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB (2012) Healthcare costs and Workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012:913848. https:\/\/doi.org\/10.1155\/2012\/913848","journal-title":"Chemother Res Pract"},{"issue":"1","key":"4773_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4149\/neo_2022_221007N992","volume":"70","author":"Z Michalova","year":"2023","unstructured":"Michalova Z, Szekiova E, Blasko J, Vanicky I (2023) Prevention and therapy of chemotherapy-induced peripheral neuropathy: a review of recent findings. Neoplasma 70(1):15\u201335. https:\/\/doi.org\/10.4149\/neo_2022_221007N992","journal-title":"Neoplasma"},{"key":"4773_CR10","doi-asserted-by":"publisher","unstructured":"Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T et al (2013) Effect of Duloxetine on pain, function, and quality of life among patients with Chemotherapy-Induced painful peripheral neuropathy. JAMA 309(13). https:\/\/doi.org\/10.1001\/jama.2013.2813","DOI":"10.1001\/jama.2013.2813"},{"issue":"7","key":"4773_CR11","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1093\/brain\/awaa098","volume":"143","author":"AR Gafson","year":"2020","unstructured":"Gafson AR, Barthelemy NR, Bomont P, Carare RO, Durham HD, Julien JP et al (2020) Neurofilaments: Neurobiological foundations for biomarker applications. Brain 143(7):1975\u20131998. https:\/\/doi.org\/10.1093\/brain\/awaa098","journal-title":"Brain"},{"issue":"4","key":"4773_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/2211068215589580","volume":"21","author":"DH Wilson","year":"2016","unstructured":"Wilson DH, Rissin DM, Kan CW, Fournier DR, Piech T, Campbell TG et al (2016) The Simoa HD-1 analyzer: A novel fully automated digital immunoassay analyzer with Single-Molecule sensitivity and multiplexing. J Lab Autom 21(4):533\u2013547. https:\/\/doi.org\/10.1177\/2211068215589580","journal-title":"J Lab Autom"},{"issue":"7","key":"4773_CR13","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1007\/s00204-020-02755-w","volume":"94","author":"C Meregalli","year":"2020","unstructured":"Meregalli C, Fumagalli G, Alberti P, Canta A, Chiorazzi A, Monza L et al (2020) Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced peripheral neurotoxicity. Arch Toxicol 94(7):2517\u20132522. https:\/\/doi.org\/10.1007\/s00204-020-02755-w","journal-title":"Arch Toxicol"},{"issue":"10","key":"4773_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14(10):577\u2013589. https:\/\/doi.org\/10.1038\/s41582-018-0058-z","journal-title":"Nat Rev Neurol"},{"key":"4773_CR15","doi-asserted-by":"publisher","unstructured":"Huehnchen P, Schinke C, Bangemann N, Dordevic AD, Kern J, Maierhof SK et al (2022) Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI Insight 7(6). https:\/\/doi.org\/10.1172\/jci.insight.154395","DOI":"10.1172\/jci.insight.154395"},{"issue":"2","key":"4773_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/jns.12493","volume":"27","author":"S Karteri","year":"2022","unstructured":"Karteri S, Bruna J, Argyriou AA, Mariotto S, Velasco R, Alemany M et al (2022) Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients. J Peripher Nerv Syst 27(2):166\u2013174. https:\/\/doi.org\/10.1111\/jns.12493","journal-title":"J Peripher Nerv Syst"},{"issue":"7","key":"4773_CR17","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1097\/j.pain.0000000000002840","volume":"164","author":"C Mortensen","year":"2023","unstructured":"Mortensen C, Steffensen KD, Simonsen E, Herskind K, Madsen JS, Olsen DA et al (2023) Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer. Pain 164(7):1502\u20131511. https:\/\/doi.org\/10.1097\/j.pain.0000000000002840","journal-title":"Pain"},{"key":"4773_CR18","doi-asserted-by":"publisher","unstructured":"Cavaletti G, Pizzamiglio C, Man A, Engber TM, Comi C, Wilbraham D (2023) Studies to assess the utility of serum neurofilament light chain as a biomarker in Chemotherapy-Induced peripheral neuropathy. Cancers (Basel) 15(17). https:\/\/doi.org\/10.3390\/cancers15174216","DOI":"10.3390\/cancers15174216"},{"issue":"6","key":"4773_CR19","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1007\/s00415-023-11624-2","volume":"270","author":"N Cebulla","year":"2023","unstructured":"Cebulla N, Schirmer D, Runau E, Flamm L, Gommersbach S, Stengel H et al (2023) Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment. J Neurol 270(6):2997\u20133007. https:\/\/doi.org\/10.1007\/s00415-023-11624-2","journal-title":"J Neurol"},{"issue":"9","key":"4773_CR20","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00415-020-09942-w","volume":"268","author":"L Kang","year":"2021","unstructured":"Kang L, Tian Y, Xu S, Chen H (2021) Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment. J Neurol 268(9):3269\u20133282. https:\/\/doi.org\/10.1007\/s00415-020-09942-w","journal-title":"J Neurol"},{"key":"4773_CR21","doi-asserted-by":"publisher","first-page":"110062","DOI":"10.1016\/j.neuropharm.2024.110062","volume":"258","author":"C Mortensen","year":"2024","unstructured":"Mortensen C, Thomsen MT, Chua KC, Hammer HS, Nielsen F, Potz O et al (2024) Modeling mechanisms of chemotherapy-induced peripheral neuropathy and chemotherapy transport using induced pluripotent stem cell-derived sensory neurons. Neuropharmacology 258:110062. https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110062","journal-title":"Neuropharmacology"},{"key":"4773_CR22","doi-asserted-by":"publisher","unstructured":"Mortensen C, Andersen NE, Stage TB (2022) Bridging the translational gap in Chemotherapy-Induced peripheral neuropathy with iPSC-Based modeling. Cancers (Basel) 14(16). https:\/\/doi.org\/10.3390\/cancers14163939","DOI":"10.3390\/cancers14163939"},{"key":"4773_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jclinepi.2021.08.001","volume":"142","author":"JC Digitale","year":"2022","unstructured":"Digitale JC, Martin JN, Glymour MM (2022) Tutorial on directed acyclic graphs. J Clin Epidemiol 142:264\u2013267. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.08.001","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"4773_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/00365513.2020.1730434","volume":"80","author":"C Vinter","year":"2020","unstructured":"Vinter C, Hviid B, Knudsen CS, Parkner T (2020) Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults. Scand J Clin Lab Investig 80(4):291\u2013295. https:\/\/doi.org\/10.1080\/00365513.2020.1730434","journal-title":"Scand J Clin Lab Investig"},{"key":"4773_CR25","doi-asserted-by":"publisher","unstructured":"Mortensen C, Chua KC, Hammer HS, Nielsen F, P\u00f6tz O, Svenningsen \u00c5F et al Paclitaxel- and vincristine-induced neurotoxicity and drug transport in sensory neurons. BioRxiv. 2023:2023.02.07.527432. https:\/\/doi.org\/10.1101\/2023.02.07.527432","DOI":"10.1101\/2023.02.07.527432"},{"issue":"2","key":"4773_CR26","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/cts.12912","volume":"14","author":"C Xiong","year":"2021","unstructured":"Xiong C, Chua KC, Stage TB, Priotti J, Kim J, Altman-Merino A et al (2021) Human induced pluripotent stem cell derived sensory neurons are sensitive to the neurotoxic effects of Paclitaxel. Clin Transl Sci 14(2):568\u2013581. https:\/\/doi.org\/10.1111\/cts.12912","journal-title":"Clin Transl Sci"},{"key":"4773_CR27","doi-asserted-by":"publisher","first-page":"105391","DOI":"10.1016\/j.nbd.2021.105391","volume":"155","author":"C Schinke","year":"2021","unstructured":"Schinke C, Fernandez Vallone V, Ivanov A, Peng Y, Kortvelyessy P, Nolte L et al (2021) Modeling chemotherapy induced neurotoxicity with human induced pluripotent stem cell (iPSC) -derived sensory neurons. Neurobiol Dis 155:105391. https:\/\/doi.org\/10.1016\/j.nbd.2021.105391","journal-title":"Neurobiol Dis"},{"key":"4773_CR28","doi-asserted-by":"publisher","unstructured":"Volpato V, Webber C (2020) Addressing variability in iPSC-derived models of human disease: guidelines to promote reproducibility. Dis Model Mech 13(1). https:\/\/doi.org\/10.1242\/dmm.042317","DOI":"10.1242\/dmm.042317"},{"key":"4773_CR29","doi-asserted-by":"publisher","unstructured":"Velasco R, Marco C, Domingo-Domenech E, Stradella A, Santos C, Laquente B et al (2024) Plasma neurofilament light chain levels in chemotherapy-induced peripheral neurotoxicity according to type of anticancer drug. Eur J Neurol e16369. https:\/\/doi.org\/10.1111\/ene.16369","DOI":"10.1111\/ene.16369"},{"key":"4773_CR30","doi-asserted-by":"publisher","unstructured":"Kim S-h, Choi MK, Park NY, Hyun J-w, Lee MY (2020) Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci Rep 1\u20139. https:\/\/doi.org\/10.1038\/s41598-020-64511-5","DOI":"10.1038\/s41598-020-64511-5"},{"key":"4773_CR31","doi-asserted-by":"publisher","unstructured":"Kacem H, Cimini A, d\u2019Angelo M, Castelli V (2024) Molecular and cellular involvement in CIPN. Biomedicines 12(4). https:\/\/doi.org\/10.3390\/biomedicines12040751","DOI":"10.3390\/biomedicines12040751"},{"issue":"12","key":"4773_CR32","doi-asserted-by":"publisher","first-page":"e2248593","DOI":"10.1001\/jamanetworkopen.2022.48593","volume":"5","author":"J Fundaun","year":"2022","unstructured":"Fundaun J, Kolski M, Molina-Alvarez M, Baskozos G, Schmid AB (2022) Types and concentrations of Blood-Based biomarkers in adults with peripheral neuropathies: A systematic review and Meta-analysis. JAMA Netw Open 5(12):e2248593. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.48593","journal-title":"JAMA Netw Open"},{"key":"4773_CR33","doi-asserted-by":"publisher","first-page":"110988","DOI":"10.1016\/j.diabres.2023.110988","volume":"205","author":"LL Maatta","year":"2023","unstructured":"Maatta LL, Andersen ST, Parkner T, Hviid CVB, Bjerg L, Kural MA et al (2023) Serum neurofilament light chain - A potential biomarker for polyneuropathy in type 2 diabetes? Diabetes Res Clin Pract 205:110988. https:\/\/doi.org\/10.1016\/j.diabres.2023.110988","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"4773_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12885-024-11856-z","volume":"24","author":"NL Gehr","year":"2024","unstructured":"Gehr NL, Karlsson P, Timm S, Christensen S, Hvid CA, Peric J et al (2024) Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro). BMC Cancer 24(1):168. https:\/\/doi.org\/10.1186\/s12885-024-11856-z","journal-title":"BMC Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04773-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04773-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04773-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T23:34:38Z","timestamp":1744241678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04773-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4773"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04773-w","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NBF has received consultancy fees from PharmNovo, Vertex, NeuroPN, Saniona, Nanobiotix, and Neurvati, and has undertaken consultancy work for Aarhus University with remunerated work for Biogen, Merz, and Confo Therapeutics outside the submitted work. She has received grants from IMI2PainCare an EU IMI 2 (Innovative medicines initiative) public-private consortium and the companies involved are: Grunenthal, Bayer, Eli Lilly, Esteve, and Teva, outside the submitted work. TBS has given paid lectures for Pfizer and Eisai and done consulting for Pfizer, and collaborated with Novo Nordisk A\/S, all unrelated to the work reported in the present paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}